Russ Conroy

Findings from 2 clinical trials support the approval of acalabrutinib as a treatment for patients with mantle cell lymphoma in China.

Treatment with retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy is associated with low long-term morbidity.

Adding avelumab to carboplatin plus paclitaxel appears to elicit a progression-free survival advantage compared with chemotherapy alone in those with advanced or recurrent endometrial cancer.

Efficacy and safety findings from the phase 3 GLOW trial assessing zolbetuximab and CAPOX in CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were consistent with the phase 3 SPOTLIGHT trial, according to an expert from Weill Cornell Medical College

Findings from a cohort of the Childhood Cancer Survivor Study identify a prediction model that may accurately identify childhood cancer survivors at varying risks of late kidney failure.

Human papillomavirus and p16 discordance may correlate with a worse prognosis for oropharyngeal cancer, according to data from an individual patient data analysis.

A genetic analysis indicates that multi-ancestry polygenic risk scores may be “potentially useful” in detecting risk of aggressive prostate cancer in patients of African ancestry, according to an expert from the University of Southern California.

According to phase 1b/2 HPV001 study data, VTP-200 appears to produce no serious adverse effects in patients with low-grade cervical human papillomavirus lesions.

Investigators plan to submit a communication application to seek marketing approval in China for ARX788 as therapy for HER2-positive advanced or metastatic breast cancer.

Investigators are assessing FORE8394, which received orphan drug designation from the FDA, in primary brain and central nervous system malignancies in the phase 2 FORTE trial.

Combination treatment with nivolumab and relatlimab appears to be a safe treatment option for patients with advanced melanoma who have progressed on prior anti–PD-L1 therapy.

Data from the phase 2 INNATE trial indicate that pimivalimab plus JTX-8064 also appears to be well tolerated in patients with platinum-resistant ovarian cancer.

Investigators indicate that although avoiding efficient mantle cell lymphoma treatment due to late effects may seem okay, most long-term health care needs are disease related in patients up to 70 years.

Use of a kit that prepares for gallium Ga 68 gozetotide injection in the phase 3 VISION study affirms its ability to identify patients who are suitable to receive PSMA-based radioligand for metastatic prostate cancer.

Findings from a confirmatory factor analysis appear to validate the structure of the Quality of Life in Myelodysplasia Scale in myelodysplastic syndromes.

Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.

EP0042 shows promising early clinical efficacy in patients with pretreated acute myeloid leukemia, according to investigators.

The addition of bortezomib to dexamethasone plus rituximab and cyclophosphamide appears to improve progression-free survival among those with Waldenström Macroglobulinemia.

Further research is necessary to determine whether regular DNA sequence testing for residual disease variants in patients with acute myeloid leukemia can improve outcomes.

Nirogacestat may be a noteworthy therapeutic advance for patients with desmoid tumors, according to an expert from Memorial Sloan Kettering Cancer Center.

Final analyses for pathologic response appear consistent with previous reports from the phase 3 AEGEAN trial evaluating neoadjuvant durvalumab and chemotherapy plus adjuvant durvalumab monotherapy in resectable non–small cell lung cancer.

The FDA initially issued a complete response letter for remestemcel-L in pediatric steroid-refractory acute graft-versus-host disease in October 2020, citing a need for an additional randomized, controlled trial to confirm the agent’s efficacy.

Findings from a multicenter analysis indicate that tumor lysis syndrome is a notable risk in patients with mantle cell lymphoma receiving treatment with venetoclax.

Abatacept plus ruxolitinib and screenings for concomitant respiratory muscle failure may be effective in reducing the rate of mortality related to immune checkpoint inhibitor–associated myocarditis among patients with cancer.

Camrelizumab plus apatinib demonstrates impressive anti-tumor activity in a pretreated population with recurrent or metastatic nasopharyngeal carcinoma, although further research is needed, according to an expert from Memorial Sloan Kettering Cancer Center.

The safety profile of fam-trastuzumab deruxtecan-nxki for managing HER2-expressing tumors in the DESTINY-PanTumor02 trial appears consistent with previously reported findings on the agent.

The VENTANA PD-L1 Assay becomes the only FDA-approved companion diagnostic with non–small cell lung cancer indications for 4 immunotherapy agents.

Pembrolizumab also appears to garner modest anti-tumor activity regardless of PD-L1 expression in patients with advanced thyroid cancer.

In particular, female patients who were considered obese with an advanced malignancy seem to have a higher incidence of high-grade immune-mediated adverse effects following treatment with nivolumab.

Lenvatinib and pembrolizumab’s benefit proves to be long-lasting and significant in first-line advanced renal cell carcinoma, according to an expert from University of Bari 'A. Moro'.